IN THE CLAIMS:

Claims 1 to 12 (cancelled)

Claim 13 (previously presented) A method of treatment for a mammal having a disease involving active angiogenesis with the formation of new vasculature in the mammal, said method comprising administration to the mammal of a tubulin binding agent and an inhibitor of formation of nitric oxide, the tubulin binding agent being administered to the mammal in an amount effective to cause damage to the new vasculature, the inhibitor of formation of nitric oxide being administered to the mammal in an amount sufficient to augment the effect of the tubulin binding agent.

Claim 14 (previously presented) A method according to claim 13 wherein the tubulin binding agent and inhibitor of the formation of nitric oxide are administered substantially simultaneously but separately to the mammal under treatment.

Claims 15 to 32 (cancelled)

Claim 33 (currently amended) A method of treatment for a mammal having a cancer involving a solid tumor, said method comprising administration of a tubulin binding agent and an inhibitor of the formation of nitric oxide in an amount sufficient to augment the effect of the tubulin binding agent.

Claim 34 (previously presented) A method according to claim 33 wherein the tubulin binding agent and the inhibitor of the formation of nitric oxide are administered substantially simultaneously but separately to the mammal under treatment.

Claim 35 (previously presented) A method according to claim 13 or claim 33 wherein the inhibitor of the formation of nitric oxide is an inhibitor of nitric oxide synthase.

Claim 36 (currently amended) A method according to claim 35 wherein the inhibitor of nitric oxide synthase is selected from the group consisting of a derivative of arginine, ornithine, lysine, citrulline, S-alkylthioureas and aminoguanidine.

Claim 37 (currently amended) A method according to claim 35 wherein the inhibitor of nitric oxide synthase is an N^G-substituted L-arginine selected from the group consisting of N^G-nitro-L-arginine and alkyl esters thereof, N^G-methyl-L-arginine and N^G -amino-L-arginine.

Claim 38 (previously presented) A method according to claim 36 wherein the derivative of ornithine is L-N6-(1-iminoethyl)-ornithine.

Claim 39 (previously presented) A method according to claim 36 wherein the derivative of lysine is L-N6-(1-iminoethyl)-lysine.

Claim 40 (currently amended) A method according to claim 36 wherein the derivative of

citrulline is selected from the group consisting of L-thiocitrulline, L-homothiocitrulline ~~or~~ and an S-alkylthiocitrulline.

Claim 41 (previously presented) A method according to claim 35 wherein the inhibitor of nitric oxide synthase is an aminopyridine.

Claim 42 (previously presented) A method according to claim 35 wherein the inhibitor of nitric oxide synthase is 2-amino-4-methylpyridine.

Claim 43 (currently amended) A method according to claim 13 or claim 33 wherein the tubulin binding agent is selected from the group consisting of N-acetylcolchinol and its prodrugs.

Claim 44 (previously presented) A method according to claim 13 or claim 33 wherein the tubulin binding agent is N-acetylcolchinol-O-phosphate.

Claim 45 (currently amended) A method according to claim 13 or claim 33 wherein the tubulin binding agent is selected from the group consisting of combretastin A4 and its prodrugs.

Claim 46 (currently amended) A method according to claim 13 or claim 33 wherein the tubulin binding agent is selected from the group consisting of combretastain A4 phosphate.

Claim 47 (currently amended) A method according to claim 13 or claim 33 wherein the tubulin

binding agent is selected from the group consisting of (Z)-2-methoxy-5-[2-(3, 4, 5-trimethoxyphenyl)vinyl] phenylamine and its prodrugs.

Claim 48 (currently amended) A method according to claim 35 wherein the tubulin binding agent is selected from the group consisting of N-acetylcolchinol and its prodrugs, ~~or~~ and combretastatin A4 and its prodrugs and wherein the inhibitor of nitric oxide synthase is selected from the group consisting of N^G-nitro-L-arginine or an alkyl ester thereof, N^G-methyl-L-arginine, N^G-amino-L-arginine, L-N6-(1-iminoethyl)-ornithine, LN6-(1-iminoethyl)-lysine, L-ihiocitrulline, L-homothiocitrulline, S-alkylthiocitrulline and 2-amino-4-methylpyridine.

Claim 49 (currently amended) A method according to claim 35 wherein the tubulin binding agent is selected from the group consisting of N-acetylcolchinol and ~~is~~ its prodrugs, ~~or~~ and combretastatin A4 and its prodrugs, and wherein the inhibitor of nitric oxide synthase is selected from the group consisting of N^G-nitro-L-arginine or an alkyl ester thereof and 2-amino-4-methylpyridine.

Claim 50 (cancelled)